167 related articles for article (PubMed ID: 22052798)
1. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Kolb EA; Gorlick R; Keir ST; Maris JM; Lock R; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 May; 58(5):815-8. PubMed ID: 22052798
[TBL] [Abstract][Full Text] [Related]
2. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Luistro L; He W; Smith M; Packman K; Vilenchik M; Carvajal D; Roberts J; Cai J; Berkofsky-Fessler W; Hilton H; Linn M; Flohr A; Jakob-Røtne R; Jacobsen H; Glenn K; Heimbrook D; Boylan JF
Cancer Res; 2009 Oct; 69(19):7672-80. PubMed ID: 19773430
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
[TBL] [Abstract][Full Text] [Related]
4. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
Huynh C; Poliseno L; Segura MF; Medicherla R; Haimovic A; Menendez S; Shang S; Pavlick A; Shao Y; Darvishian F; Boylan JF; Osman I; Hernando E
PLoS One; 2011; 6(9):e25264. PubMed ID: 21980408
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
[TBL] [Abstract][Full Text] [Related]
6. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
Wang L; Dai G; Yang J; Wu W; Zhang W
Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
Debeb BG; Cohen EN; Boley K; Freiter EM; Li L; Robertson FM; Reuben JM; Cristofanilli M; Buchholz TA; Woodward WA
Breast Cancer Res Treat; 2012 Jul; 134(2):495-510. PubMed ID: 22547109
[TBL] [Abstract][Full Text] [Related]
9. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
He W; Luistro L; Carvajal D; Smith M; Nevins T; Yin X; Cai J; Higgins B; Kolinsky K; Rizzo C; Packman K; Heimbrook D; Boylan JF
Mol Oncol; 2011 Jun; 5(3):292-301. PubMed ID: 21315665
[TBL] [Abstract][Full Text] [Related]
10. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.
Pisklakova A; Grigson E; Ozerova M; Chen F; Sullivan DM; Nefedova Y
Cancer Biol Ther; 2016 May; 17(5):477-85. PubMed ID: 26934342
[TBL] [Abstract][Full Text] [Related]
11. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Notch and TGF-β signaling pathways to prevent retinal fibrosis
Fan J; Shen W; Lee SR; Mathai AE; Zhang R; Xu G; Gillies MC
Theranostics; 2020; 10(18):7956-7973. PubMed ID: 32724452
[No Abstract] [Full Text] [Related]
14. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
[TBL] [Abstract][Full Text] [Related]
15. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Lyalin D
Pediatr Blood Cancer; 2014 Aug; 61(8):1493-6. PubMed ID: 24664981
[TBL] [Abstract][Full Text] [Related]
16. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
Nair JS; Sheikh T; Ho AL; Schwartz GK
Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Laheru D; Maitra A; Arcaroli J; Rudek MA; Dasari A; Blatchford PJ; Quackenbush K; Messersmith W
Invest New Drugs; 2014 Aug; 32(4):739-45. PubMed ID: 24668033
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Sardesai S; Badawi M; Mrozek E; Morgan E; Phelps M; Stephens J; Wei L; Kassem M; Ling Y; Lustberg M; Stover D; Williams N; Layman R; Reinbolt R; VanDeusen J; Cherian M; Grever M; Carson W; Ramaswamy B; Wesolowski R
Invest New Drugs; 2020 Oct; 38(5):1400-1410. PubMed ID: 31953695
[TBL] [Abstract][Full Text] [Related]
19. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma.
Wu J; Wiegand R; LoRusso P; Li J
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1537-43. PubMed ID: 21497565
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of RO4929097 in metastatic colorectal cancer.
Strosberg JR; Yeatman T; Weber J; Coppola D; Schell MJ; Han G; Almhanna K; Kim R; Valone T; Jump H; Sullivan D
Eur J Cancer; 2012 May; 48(7):997-1003. PubMed ID: 22445247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
